Merck beefing up diabetes pipeline

Merck acquires non-exclusive license for Acuform technology from Depomed Merck plans to use technology to expand it’s diabetes portfolio Signifies the extended release diabetes market is growing more competitive Pharmaceutical pipeline weaknesses will spur more deals. Today, Merck (NYSE:MRK) signaled that it will be expanding it’s diabetes pipeline. Merck announced that it has licensed certain […]

Pfizer expanding into emerging markets: Turkey

Rumors are buzzing in the pharma sector. Pfizer (NYSE:PFE) may be considering a takeover of Abdi Ibrahim, Turkey’s largest pharmaceutical company, demonstrating Pfizer’s shift from domestic markets to emerging markets. After it’s merger with Wyeth (NYSE:WYE), Pfizer’s executives organized at Castle Gray Skull and set it’s course to find it’s partners in the Middle East. […]

Noven: Mesafem is tackling the heat of hot flashes

Earlier this month, I suggested that there is a huge unmet need, and substantial market opportunity, for a potential product that will treat menopausal symptoms. We recommended several Women’s Health companies. Today, one of those companies, Noven (NASDAQ:NOVN) announced positive phase 2 trial results for Mesafem, a drug that treats vasomotor symptoms, known as “hot flashes”. […]

Johnson & Johnson Lathers Elan

Pharmacuetical Giant, Johnson & Johnson, is taking a minority stake in Ireland’s Elan 18% stake for $1 Billion USD Elan’s (NYSE:ELN) wish came true. The Irish company attracted a Big Pharma partner–Johnson & Johnson (NYSE:JNJ)–to take a minority stake, just as it’s been hoping for all along. J&J will sink $1 billion into Elan in […]

Women’s Health: Who can handle the heat for Hot Flashes?

After the Women’s Health Initiative there is an opportunity for new non-hormonal treatments for menopausal symptoms Some estimates believe this market may be up to $8 Billion USD Before the Women’s Health Initiative (‘WHI’), women were effectively treating their menopausal symptoms with hormone replacement therapy (‘HRT’), such as Premarin, Prempro and others. But since then, […]

Solvay : “Second Round” for Drug-Unit

Reuters reported that Solvay has drawn up a shortlist of potential bidders for it’s drug business. The start of a second round of the divestment process is supposed to imply that “Solvay is more serious than it has said in public about selling the business with $3.78 billion in sales.” Solvay commented on the report, […]

Santurus: Fundamentals Unchanged!

Recently, an article from Seeking Alpha has got me scratching my head! The title: “Santarus: Business Fundamentals Improving”, which was written by an analyst from Zack’s. The article highlighted recent additions to Santarus’s business plan through the in-licensing of: Glumetza, Budenoside, and Rifamycin. Furthermore, the article suggested that these additions are net positive since little-to-no […]

DepoMed: Protected by Cash and Headed Higher

Recently, my partner has made some great stock picks for his portfolio. The markets now are truly once in a lifetime and these sort of gyrations can present huge opportunities to us small time investors. His portfolio is up 75% month-over-month. I got to give him props. But let me make a case for Depomed (NASDAQ:DEPO). […]